0.07 | 0.54%
| Price and Volume | |
|---|---|
| Recent Price | 13.02 |
| 52 Week High | 18.99 |
| 52 Week Low | 8.63 |
| Avg. Daily Vol. (Mil) | 0.15 |
| Beta (3 year) | 3.40 |
| Share Related Items | |
| Mkt Cap (Mil) | 189.31 |
| Shares Out (Mil) | 14.54 |
| Float (Mil) | 14.44 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.60 |
| Current Ratio | 3.70 |
| LT Debt/ Equity | 0.08 |
| Total Debt / Equity | 0.10 |
| Valuation Ratios | |
| Price Earnings | 16.30 |
| Price/Sales | 33.73 |
| Price/Book | 2.42 |
| Price/Cash Flow | -10.30 |
| Per Share Data | |
| Earnings | 0.80 |
| Sales | 0.39 |
| Book Value | 5.37 |
| Cash Flow | -1.27 |
| Business Summary | |
|---|---|
| OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical Company engaged in the development and commercialization of new therapies that address unmet needs in the treatment of cancer. | |
| General Information | |
| 1522 - 217th Place SE
Suite 100 Bothell, WA 98021 |
|
| www.oncogenex.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 32 | |
| CEO: Mr. Scott Cormack | |
| Short Interest | |
| Current Month (Mil) | 0.64 |
| Previous Month (Mil) | 0.63 |
| Short Interest Ratio (Days) | 8.70 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -16.00 |
| Return on Investments | -21.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,580.69 | 1,332.42 | 2,870.99 | 17.31 |
Oil *
106.79
|
|
UP
125.86 |
UP
14.60 |
UP
33.46 |
DOWN
0.14 |
10 Yr
1.73%
SPDR Gold
151.02
|
|
+1.01%
|
+1.11%
|
+1.18%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet